NCT03305380View on ClinicalTrials.gov

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

CompletedOBSERVATIONAL
Enrollment

637

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

January 1, 2021

Study Completion Date

April 1, 2021

Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
OTHER

No interventions

As this is a patient registry, there are no interventions.

Trial Locations (2)

6419 PC

Zuyderland Medical Center, Heerlen

6229 HX

MUMC+, Maastricht

All Listed Sponsors
collaborator

Maastricht University Medical Center

OTHER

collaborator

Zuyderland Medical Centre

OTHER

lead

Maastricht Radiation Oncology

OTHER

NCT03305380 - Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth | Biotech Hunter | Biotech Hunter